These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27527911)

  • 1. Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.
    Frías JP; Nakhle S; Ruggles JA; Zhuplatov S; Klein E; Zhou R; Strange P
    Diabetes Obes Metab; 2017 Jan; 19(1):40-48. PubMed ID: 27527911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
    Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
    Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exenatide once weekly combined with metformin reduced glycemic variability in type 2 diabetes by using flash glucose monitoring system.
    Li Y; Han MM; He Q; Liu ZA; Liang D; Hou JT; Zhang Y; Liu YF
    World J Diabetes; 2020 Dec; 11(12):654-665. PubMed ID: 33384771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study.
    Thomsen MN; Skytte MJ; Astrup A; Deacon CF; Holst JJ; Madsbad S; Krarup T; Haugaard SB; Samkani A
    Clin Nutr ESPEN; 2020 Oct; 39():46-52. PubMed ID: 32859328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
    Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
    Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial.
    Wang L; Liu X; Yang W; Lai J; Yu X; Liu J; Gao X; Ming J; Ma K; Xu J; Tian Z; He Q; Ji Q
    Diabetes Ther; 2020 Oct; 11(10):2313-2328. PubMed ID: 32856226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved glycaemic variability and time in range with dapagliflozin versus gliclazide modified release among adults with type 2 diabetes, evaluated by continuous glucose monitoring: A 12-week randomized controlled trial.
    Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Scharf M; Detsch JM; Marques K; Sanches CP
    Diabetes Obes Metab; 2020 Apr; 22(4):501-511. PubMed ID: 31709738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections.
    Sofizadeh S; Imberg H; Ólafsdóttir AF; Ekelund M; Dahlqvist S; Hirsch I; Filipsson K; Ahrén B; Sjöberg S; Tuomilehto J; Lind M
    Diabetes Ther; 2019 Dec; 10(6):2115-2130. PubMed ID: 31564026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.
    Pereira MJ; Lundkvist P; Kamble PG; Lau J; Martins JG; Sjöström CD; Schnecke V; Walentinsson A; Johnsson E; Eriksson JW
    Diabetes Ther; 2018 Aug; 9(4):1511-1532. PubMed ID: 29949016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
    Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).
    Bolli GB; Munteanu M; Dotsenko S; Niemoeller E; Boka G; Wu Y; Hanefeld M
    Diabet Med; 2014 Feb; 31(2):176-84. PubMed ID: 24117597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the GLP-1 Receptor Agonist Exenatide on Impaired Awareness of Hypoglycemia in Type 1 Diabetes: A Randomized Controlled Trial.
    van Meijel LA; Rooijackers HM; Tack CJ; de Galan BE
    J Clin Endocrinol Metab; 2019 Sep; 104(9):4143-4150. PubMed ID: 30958544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.